Aceragen Launches with Acquisition of Enzyvant’s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest
Acquires worldwide rights to RVT-801, a novel enzyme replacement therapy for treatment of Farber disease NovaQuest investment to fund product and clinical development Protocol for potential single registration study reviewed with FDA and EMA Program has been granted rare pediatric disease status, fast track and orphan designations, and is eligible for a priority review voucher
